Conjunctivitis Treatment Market By Drug Class (Antibiotics, Antiviral, Anti-allergic, Artificial Tears), By Disease Type (Allergic Conjunctivitis, Bacterial Conjunctivitis, Viral Conjunctivitis), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy
Description
Conjunctivitis Treatment Market By Drug Class (Antibiotics, Antiviral, Anti-allergic, Artificial Tears), By Disease Type (Allergic Conjunctivitis, Bacterial Conjunctivitis, Viral Conjunctivitis), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global conjunctivitis treatment market was valued at $4,213.01 million in 2021, and is projected to reach $6,117.28 million by 2031, registering a CAGR of 3.8% from 2022 to 2031.
Conjunctivitis refers to the inflammation or infection of the conjunctiva. It is the most common presentation of eye redness in both primary care and the emergency department, therefore putting a large strain on the healthcare system. Conjunctivitis is a common cause of eye redness and subsequently a common complaint in the emergency department, urgent care, and primary care clinics. It can affect people of any age, demographic or socioeconomic status. Although usually self-limiting and rarely resulting in vision loss, when assessing for conjunctivitis, it is essential to rule out other sight-threatening causes of red-eye. The conjunctiva is the transparent, lubricating mucous membrane covering the outer surface of the eye. It is composed of two parts, the “bulbar conjunctiva” which covers the globe and the “tarsal conjunctiva” which lines the eyelid's inner surface. Conjunctivitis refers to the inflammation or infection of the conjunctiva. It can be acute or chronic and infectious or non-infectious. Acute conjunctivitis refers to symptom duration 3 to 4 weeks from presentation (usually only lasting 1 to 2 weeks) whereas chronic is defined as lasting more than 4 weeks.
Increase in access to diagnostic tests for conjunctivitis, rise in R&D activities by the market players, surge in strategic collaborations among the market players, and increase in product launches and approvals are expected to drive the growth of the global conjunctivitis treatment market. In addition, focus of governments on awareness programs, and rise in healthcare expenditure and pollution propel the growth of the conjunctivitis treatment market. Further, different technologies employed in the development of effective treatment boost the market growth.
However, high monetary inputs associated with manufacturing of the products restrict the growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market during the forecast period.
The conjunctivitis treatment market is segmented on the basis of disease type, drug class, distribution channel, and region. By disease type, it is categorized into allergic conjunctivitis, bacterial conjunctivitis, and viral conjunctivitis. By drug class, it is classified into antibiotics, antiviral, anti-allergic, and artificial tears. By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
By disease type, the allergic conjunctivitis segment generated the highest revenue in the conjunctivitis treatment market in 2021 owing to increase in prevalence of allergic conjunctivitis. By drug class, the anti-allergic segment generated the highest revenue in the conjunctivitis treatment market in 2021, owing to advancements in anti-allergic drugs and new product launch. By distribution channel, the hospital pharmacy segment generated the highest revenue in the conjunctivitis treatment market in 2021, owing to increase in number of hospital pharmacy.
By region, North America accounted for the largest market share in the conjunctivitis treatment market in 2021 and is expected to retain its dominance throughout the forecast period. This is primarily attributed to increase in prevalence of conjunctivitis, presence of well-established healthcare infrastructure and rise in healthcare expenditure.
Asia-Pacific witnessed the highest growth rate for the conjunctivitis treatment market and is expected to continue this trend throughout the forecast period, which is attributed to presence of high population base and increase in healthcare expenditure.
The report provides a comprehensive analysis of the key players that operate in the global conjunctivitis treatment market. The key companies profiled in the report include AbbVie Inc., Ajanta Pharma Limited, AFT pharmaceuticals, Alembic Pharmaceuticals Ltd, Bausch Health Companies Inc , Cipla, Inc., Grevis Pharmaceutical Private Limited , Indoco Remedies Ltd., Jabs Biotech Pvt. Ltd., JAWA Pharmaceuticals Pvt. Ltd, Johnson & Johnson Services Inc., , Novartis AG, , Ocular Therapeutics, Inc., Santen Pharmaceuticals Co. Ltd., Spectra Vision Care Pvt. Ltd, Sun Pharmaceuticals Industries Ltd and Teva Pharmaceutical Industries Ltd.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the conjunctivitis treatment market analysis from 2021 to 2031 to identify the prevailing conjunctivitis treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the conjunctivitis treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global conjunctivitis treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Class
Antibiotics
Antiviral
Anti-allergic
Artificial Tears
By Disease Type
Allergic Conjunctivitis
Type
Seasonal Allergic Conjunctivitis
Perennial Allergic Conjunctivitis
Bacterial Conjunctivitis
Viral Conjunctivitis
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Abbvie Inc
Ajanta Pharma Limited
AFT Pharmaceuticals
Alembic Pharmaceuticals Ltd
Bausch Health Companies Inc
Cipla, Inc.
Grevis Pharmaceutical Private Limited
Indoco Remedies Ltd.
Jabs Biotech Pvt. Ltd.
JAWA Pharmaceuticals Pvt. Ltd
Johnson & Johnson Services Inc
Novartis AG
Ocular Therapeutics, Inc
Santen Pharmaceuticals Co. Ltd.
Spectra Vision Care Pvt. Ltd
Sun Pharmaceuticals Industries Ltd
Teva Pharmaceutical Industries Ltd
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
The global conjunctivitis treatment market was valued at $4,213.01 million in 2021, and is projected to reach $6,117.28 million by 2031, registering a CAGR of 3.8% from 2022 to 2031.
Conjunctivitis refers to the inflammation or infection of the conjunctiva. It is the most common presentation of eye redness in both primary care and the emergency department, therefore putting a large strain on the healthcare system. Conjunctivitis is a common cause of eye redness and subsequently a common complaint in the emergency department, urgent care, and primary care clinics. It can affect people of any age, demographic or socioeconomic status. Although usually self-limiting and rarely resulting in vision loss, when assessing for conjunctivitis, it is essential to rule out other sight-threatening causes of red-eye. The conjunctiva is the transparent, lubricating mucous membrane covering the outer surface of the eye. It is composed of two parts, the “bulbar conjunctiva” which covers the globe and the “tarsal conjunctiva” which lines the eyelid's inner surface. Conjunctivitis refers to the inflammation or infection of the conjunctiva. It can be acute or chronic and infectious or non-infectious. Acute conjunctivitis refers to symptom duration 3 to 4 weeks from presentation (usually only lasting 1 to 2 weeks) whereas chronic is defined as lasting more than 4 weeks.
Increase in access to diagnostic tests for conjunctivitis, rise in R&D activities by the market players, surge in strategic collaborations among the market players, and increase in product launches and approvals are expected to drive the growth of the global conjunctivitis treatment market. In addition, focus of governments on awareness programs, and rise in healthcare expenditure and pollution propel the growth of the conjunctivitis treatment market. Further, different technologies employed in the development of effective treatment boost the market growth.
However, high monetary inputs associated with manufacturing of the products restrict the growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market during the forecast period.
The conjunctivitis treatment market is segmented on the basis of disease type, drug class, distribution channel, and region. By disease type, it is categorized into allergic conjunctivitis, bacterial conjunctivitis, and viral conjunctivitis. By drug class, it is classified into antibiotics, antiviral, anti-allergic, and artificial tears. By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
By disease type, the allergic conjunctivitis segment generated the highest revenue in the conjunctivitis treatment market in 2021 owing to increase in prevalence of allergic conjunctivitis. By drug class, the anti-allergic segment generated the highest revenue in the conjunctivitis treatment market in 2021, owing to advancements in anti-allergic drugs and new product launch. By distribution channel, the hospital pharmacy segment generated the highest revenue in the conjunctivitis treatment market in 2021, owing to increase in number of hospital pharmacy.
By region, North America accounted for the largest market share in the conjunctivitis treatment market in 2021 and is expected to retain its dominance throughout the forecast period. This is primarily attributed to increase in prevalence of conjunctivitis, presence of well-established healthcare infrastructure and rise in healthcare expenditure.
Asia-Pacific witnessed the highest growth rate for the conjunctivitis treatment market and is expected to continue this trend throughout the forecast period, which is attributed to presence of high population base and increase in healthcare expenditure.
The report provides a comprehensive analysis of the key players that operate in the global conjunctivitis treatment market. The key companies profiled in the report include AbbVie Inc., Ajanta Pharma Limited, AFT pharmaceuticals, Alembic Pharmaceuticals Ltd, Bausch Health Companies Inc , Cipla, Inc., Grevis Pharmaceutical Private Limited , Indoco Remedies Ltd., Jabs Biotech Pvt. Ltd., JAWA Pharmaceuticals Pvt. Ltd, Johnson & Johnson Services Inc., , Novartis AG, , Ocular Therapeutics, Inc., Santen Pharmaceuticals Co. Ltd., Spectra Vision Care Pvt. Ltd, Sun Pharmaceuticals Industries Ltd and Teva Pharmaceutical Industries Ltd.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the conjunctivitis treatment market analysis from 2021 to 2031 to identify the prevailing conjunctivitis treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the conjunctivitis treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global conjunctivitis treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Class
Antibiotics
Antiviral
Anti-allergic
Artificial Tears
By Disease Type
Allergic Conjunctivitis
Type
Seasonal Allergic Conjunctivitis
Perennial Allergic Conjunctivitis
Bacterial Conjunctivitis
Viral Conjunctivitis
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Abbvie Inc
Ajanta Pharma Limited
AFT Pharmaceuticals
Alembic Pharmaceuticals Ltd
Bausch Health Companies Inc
Cipla, Inc.
Grevis Pharmaceutical Private Limited
Indoco Remedies Ltd.
Jabs Biotech Pvt. Ltd.
JAWA Pharmaceuticals Pvt. Ltd
Johnson & Johnson Services Inc
Novartis AG
Ocular Therapeutics, Inc
Santen Pharmaceuticals Co. Ltd.
Spectra Vision Care Pvt. Ltd
Sun Pharmaceuticals Industries Ltd
Teva Pharmaceutical Industries Ltd
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Table of Contents
220 Pages
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Antibiotics
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Antiviral
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 Anti-allergic
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- 4.5 Artificial Tears
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
- CHAPTER 5: CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Allergic Conjunctivitis
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.2.4 Allergic Conjunctivitis Conjunctivitis Treatment Market by Type
- 5.2.4.1 Seasonal Allergic Conjunctivitis Market size and forecast, by region
- 5.2.4.2 Perennial Allergic Conjunctivitis Market size and forecast, by region
- 5.3 Bacterial Conjunctivitis
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Viral Conjunctivitis
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- CHAPTER 6: CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Hospital Pharmacy
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Retail Pharmacy
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Online Pharmacy
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
- CHAPTER 7: CONJUNCTIVITIS TREATMENT MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Drug Class
- 7.2.3 North America Market size and forecast, by Disease Type
- 7.2.3.1 North America Allergic Conjunctivitis Conjunctivitis Treatment Market by Type
- 7.2.4 North America Market size and forecast, by Distribution Channel
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Drug Class
- 7.2.5.1.2 Market size and forecast, by Disease Type
- 7.2.5.1.3 Market size and forecast, by Distribution Channel
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Drug Class
- 7.2.5.2.2 Market size and forecast, by Disease Type
- 7.2.5.2.3 Market size and forecast, by Distribution Channel
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Drug Class
- 7.2.5.3.2 Market size and forecast, by Disease Type
- 7.2.5.3.3 Market size and forecast, by Distribution Channel
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Drug Class
- 7.3.3 Europe Market size and forecast, by Disease Type
- 7.3.3.1 Europe Allergic Conjunctivitis Conjunctivitis Treatment Market by Type
- 7.3.4 Europe Market size and forecast, by Distribution Channel
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Drug Class
- 7.3.5.1.2 Market size and forecast, by Disease Type
- 7.3.5.1.3 Market size and forecast, by Distribution Channel
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Drug Class
- 7.3.5.2.2 Market size and forecast, by Disease Type
- 7.3.5.2.3 Market size and forecast, by Distribution Channel
- 7.3.5.3 UK
- 7.3.5.3.1 Market size and forecast, by Drug Class
- 7.3.5.3.2 Market size and forecast, by Disease Type
- 7.3.5.3.3 Market size and forecast, by Distribution Channel
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Drug Class
- 7.3.5.4.2 Market size and forecast, by Disease Type
- 7.3.5.4.3 Market size and forecast, by Distribution Channel
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Drug Class
- 7.3.5.5.2 Market size and forecast, by Disease Type
- 7.3.5.5.3 Market size and forecast, by Distribution Channel
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Drug Class
- 7.3.5.6.2 Market size and forecast, by Disease Type
- 7.3.5.6.3 Market size and forecast, by Distribution Channel
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Drug Class
- 7.4.3 Asia-Pacific Market size and forecast, by Disease Type
- 7.4.3.1 Asia-Pacific Allergic Conjunctivitis Conjunctivitis Treatment Market by Type
- 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 Japan
- 7.4.5.1.1 Market size and forecast, by Drug Class
- 7.4.5.1.2 Market size and forecast, by Disease Type
- 7.4.5.1.3 Market size and forecast, by Distribution Channel
- 7.4.5.2 China
- 7.4.5.2.1 Market size and forecast, by Drug Class
- 7.4.5.2.2 Market size and forecast, by Disease Type
- 7.4.5.2.3 Market size and forecast, by Distribution Channel
- 7.4.5.3 Australia
- 7.4.5.3.1 Market size and forecast, by Drug Class
- 7.4.5.3.2 Market size and forecast, by Disease Type
- 7.4.5.3.3 Market size and forecast, by Distribution Channel
- 7.4.5.4 India
- 7.4.5.4.1 Market size and forecast, by Drug Class
- 7.4.5.4.2 Market size and forecast, by Disease Type
- 7.4.5.4.3 Market size and forecast, by Distribution Channel
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by Drug Class
- 7.4.5.5.2 Market size and forecast, by Disease Type
- 7.4.5.5.3 Market size and forecast, by Distribution Channel
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Market size and forecast, by Drug Class
- 7.4.5.6.2 Market size and forecast, by Disease Type
- 7.4.5.6.3 Market size and forecast, by Distribution Channel
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Drug Class
- 7.5.3 LAMEA Market size and forecast, by Disease Type
- 7.5.3.1 LAMEA Allergic Conjunctivitis Conjunctivitis Treatment Market by Type
- 7.5.4 LAMEA Market size and forecast, by Distribution Channel
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Drug Class
- 7.5.5.1.2 Market size and forecast, by Disease Type
- 7.5.5.1.3 Market size and forecast, by Distribution Channel
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Drug Class
- 7.5.5.2.2 Market size and forecast, by Disease Type
- 7.5.5.2.3 Market size and forecast, by Distribution Channel
- 7.5.5.3 South Africa
- 7.5.5.3.1 Market size and forecast, by Drug Class
- 7.5.5.3.2 Market size and forecast, by Disease Type
- 7.5.5.3.3 Market size and forecast, by Distribution Channel
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Market size and forecast, by Drug Class
- 7.5.5.4.2 Market size and forecast, by Disease Type
- 7.5.5.4.3 Market size and forecast, by Distribution Channel
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 Abbvie Inc
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Ajanta Pharma Limited
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 AFT Pharmaceuticals
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 Alembic Pharmaceuticals Ltd
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Bausch Health Companies Inc
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Cipla, Inc.
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Grevis Pharmaceutical Private Limited
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Indoco Remedies Ltd.
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Jabs Biotech Pvt. Ltd.
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 JAWA Pharmaceuticals Pvt. Ltd
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- 9.11 Johnson & Johnson Services Inc
- 9.11.1 Company overview
- 9.11.2 Company snapshot
- 9.11.3 Operating business segments
- 9.11.4 Product portfolio
- 9.11.5 Business performance
- 9.11.6 Key strategic moves and developments
- 9.12 Novartis AG
- 9.12.1 Company overview
- 9.12.2 Company snapshot
- 9.12.3 Operating business segments
- 9.12.4 Product portfolio
- 9.12.5 Business performance
- 9.12.6 Key strategic moves and developments
- 9.13 Ocular Therapeutics, Inc
- 9.13.1 Company overview
- 9.13.2 Company snapshot
- 9.13.3 Operating business segments
- 9.13.4 Product portfolio
- 9.13.5 Business performance
- 9.13.6 Key strategic moves and developments
- 9.14 Santen Pharmaceuticals Co. Ltd.
- 9.14.1 Company overview
- 9.14.2 Company snapshot
- 9.14.3 Operating business segments
- 9.14.4 Product portfolio
- 9.14.5 Business performance
- 9.14.6 Key strategic moves and developments
- 9.15 Spectra Vision Care Pvt. Ltd
- 9.15.1 Company overview
- 9.15.2 Company snapshot
- 9.15.3 Operating business segments
- 9.15.4 Product portfolio
- 9.15.5 Business performance
- 9.15.6 Key strategic moves and developments
- 9.16 Sun Pharmaceuticals Industries Ltd
- 9.16.1 Company overview
- 9.16.2 Company snapshot
- 9.16.3 Operating business segments
- 9.16.4 Product portfolio
- 9.16.5 Business performance
- 9.16.6 Key strategic moves and developments
- 9.17 Teva Pharmaceutical Industries Ltd
- 9.17.1 Company overview
- 9.17.2 Company snapshot
- 9.17.3 Operating business segments
- 9.17.4 Product portfolio
- 9.17.5 Business performance
- 9.17.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 2. CONJUNCTIVITIS TREATMENT MARKET SIZE, FOR ANTIBIOTICS, BY REGION, 2021-2031 ($MILLION)
- TABLE 3. CONJUNCTIVITIS TREATMENT MARKET FOR ANTIBIOTICS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 4. CONJUNCTIVITIS TREATMENT MARKET SIZE, FOR ANTIVIRAL, BY REGION, 2021-2031 ($MILLION)
- TABLE 5. CONJUNCTIVITIS TREATMENT MARKET FOR ANTIVIRAL, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 6. CONJUNCTIVITIS TREATMENT MARKET SIZE, FOR ANTI-ALLERGIC, BY REGION, 2021-2031 ($MILLION)
- TABLE 7. CONJUNCTIVITIS TREATMENT MARKET FOR ANTI-ALLERGIC, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 8. CONJUNCTIVITIS TREATMENT MARKET SIZE, FOR ARTIFICIAL TEARS, BY REGION, 2021-2031 ($MILLION)
- TABLE 9. CONJUNCTIVITIS TREATMENT MARKET FOR ARTIFICIAL TEARS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 10. GLOBAL CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 11. CONJUNCTIVITIS TREATMENT MARKET SIZE, FOR ALLERGIC CONJUNCTIVITIS, BY REGION, 2021-2031 ($MILLION)
- TABLE 12. CONJUNCTIVITIS TREATMENT MARKET FOR ALLERGIC CONJUNCTIVITIS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 13. GLOBAL ALLERGIC CONJUNCTIVITIS CONJUNCTIVITIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 14. CONJUNCTIVITIS TREATMENT MARKET, FOR SEASONAL ALLERGIC CONJUNCTIVITIS, BY REGION, 2021-2031 ($MILLION)
- TABLE 15. CONJUNCTIVITIS TREATMENT MARKET, FOR PERENNIAL ALLERGIC CONJUNCTIVITIS, BY REGION, 2021-2031 ($MILLION)
- TABLE 16. CONJUNCTIVITIS TREATMENT MARKET SIZE, FOR BACTERIAL CONJUNCTIVITIS, BY REGION, 2021-2031 ($MILLION)
- TABLE 17. CONJUNCTIVITIS TREATMENT MARKET FOR BACTERIAL CONJUNCTIVITIS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 18. CONJUNCTIVITIS TREATMENT MARKET SIZE, FOR VIRAL CONJUNCTIVITIS, BY REGION, 2021-2031 ($MILLION)
- TABLE 19. CONJUNCTIVITIS TREATMENT MARKET FOR VIRAL CONJUNCTIVITIS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 20. GLOBAL CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 21. CONJUNCTIVITIS TREATMENT MARKET SIZE, FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 ($MILLION)
- TABLE 22. CONJUNCTIVITIS TREATMENT MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 23. CONJUNCTIVITIS TREATMENT MARKET SIZE, FOR RETAIL PHARMACY, BY REGION, 2021-2031 ($MILLION)
- TABLE 24. CONJUNCTIVITIS TREATMENT MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 25. CONJUNCTIVITIS TREATMENT MARKET SIZE, FOR ONLINE PHARMACY, BY REGION, 2021-2031 ($MILLION)
- TABLE 26. CONJUNCTIVITIS TREATMENT MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 27. CONJUNCTIVITIS TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 28. NORTH AMERICA CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 29. NORTH AMERICA CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 30. NORTH AMERICA ALLERGIC CONJUNCTIVITIS CONJUNCTIVITIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 31. NORTH AMERICA CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 32. NORTH AMERICA CONJUNCTIVITIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 33. U.S. CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 34. U.S. CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 35. U.S. CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 36. CANADA CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 37. CANADA CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 38. CANADA CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 39. MEXICO CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 40. MEXICO CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 41. MEXICO CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 42. EUROPE CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 43. EUROPE CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 44. EUROPE ALLERGIC CONJUNCTIVITIS CONJUNCTIVITIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 45. EUROPE CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 46. EUROPE CONJUNCTIVITIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 47. GERMANY CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 48. GERMANY CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 49. GERMANY CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 50. FRANCE CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 51. FRANCE CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 52. FRANCE CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 53. UK CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 54. UK CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 55. UK CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 56. ITALY CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 57. ITALY CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 58. ITALY CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 59. SPAIN CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 60. SPAIN CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 61. SPAIN CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 62. REST OF EUROPE CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 63. REST OF EUROPE CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 64. REST OF EUROPE CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 65. ASIA-PACIFIC CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 66. ASIA-PACIFIC CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 67. ASIA-PACIFIC ALLERGIC CONJUNCTIVITIS CONJUNCTIVITIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 68. ASIA-PACIFIC CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 69. ASIA-PACIFIC CONJUNCTIVITIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 70. JAPAN CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 71. JAPAN CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 72. JAPAN CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 73. CHINA CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 74. CHINA CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 75. CHINA CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 76. AUSTRALIA CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 77. AUSTRALIA CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 78. AUSTRALIA CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 79. INDIA CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 80. INDIA CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 81. INDIA CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 82. SOUTH KOREA CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 83. SOUTH KOREA CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 84. SOUTH KOREA CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 85. REST OF ASIA-PACIFIC CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 86. REST OF ASIA-PACIFIC CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 87. REST OF ASIA-PACIFIC CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 88. LAMEA CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 89. LAMEA CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 90. LAMEA ALLERGIC CONJUNCTIVITIS CONJUNCTIVITIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 91. LAMEA CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 92. LAMEA CONJUNCTIVITIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 93. BRAZIL CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 94. BRAZIL CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 95. BRAZIL CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 96. SAUDI ARABIA CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 97. SAUDI ARABIA CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 98. SAUDI ARABIA CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 99. SOUTH AFRICA CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 100. SOUTH AFRICA CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 101. SOUTH AFRICA CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 102. REST OF LAMEA CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 103. REST OF LAMEA CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 104. REST OF LAMEA CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 105.ABBVIE INC: COMPANY SNAPSHOT
- TABLE 106.ABBVIE INC: OPERATING SEGMENTS
- TABLE 107.ABBVIE INC: PRODUCT PORTFOLIO
- TABLE 108.ABBVIE INC: NET SALES,
- TABLE 109.ABBVIE INC: KEY STRATERGIES
- TABLE 110.AJANTA PHARMA LIMITED: COMPANY SNAPSHOT
- TABLE 111.AJANTA PHARMA LIMITED: OPERATING SEGMENTS
- TABLE 112.AJANTA PHARMA LIMITED: PRODUCT PORTFOLIO
- TABLE 113.AJANTA PHARMA LIMITED: NET SALES,
- TABLE 114.AJANTA PHARMA LIMITED: KEY STRATERGIES
- TABLE 115.AFT PHARMACEUTICALS: COMPANY SNAPSHOT
- TABLE 116.AFT PHARMACEUTICALS: OPERATING SEGMENTS
- TABLE 117.AFT PHARMACEUTICALS: PRODUCT PORTFOLIO
- TABLE 118.AFT PHARMACEUTICALS: NET SALES,
- TABLE 119.AFT PHARMACEUTICALS: KEY STRATERGIES
- TABLE 120.ALEMBIC PHARMACEUTICALS LTD: COMPANY SNAPSHOT
- TABLE 121.ALEMBIC PHARMACEUTICALS LTD: OPERATING SEGMENTS
- TABLE 122.ALEMBIC PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
- TABLE 123.ALEMBIC PHARMACEUTICALS LTD: NET SALES,
- TABLE 124.ALEMBIC PHARMACEUTICALS LTD: KEY STRATERGIES
- TABLE 125.BAUSCH HEALTH COMPANIES INC: COMPANY SNAPSHOT
- TABLE 126.BAUSCH HEALTH COMPANIES INC: OPERATING SEGMENTS
- TABLE 127.BAUSCH HEALTH COMPANIES INC: PRODUCT PORTFOLIO
- TABLE 128.BAUSCH HEALTH COMPANIES INC: NET SALES,
- TABLE 129.BAUSCH HEALTH COMPANIES INC: KEY STRATERGIES
- TABLE 130.CIPLA, INC.: COMPANY SNAPSHOT
- TABLE 131.CIPLA, INC.: OPERATING SEGMENTS
- TABLE 132.CIPLA, INC.: PRODUCT PORTFOLIO
- TABLE 133.CIPLA, INC.: NET SALES,
- TABLE 134.CIPLA, INC.: KEY STRATERGIES
- TABLE 135.GREVIS PHARMACEUTICAL PRIVATE LIMITED: COMPANY SNAPSHOT
- TABLE 136.GREVIS PHARMACEUTICAL PRIVATE LIMITED: OPERATING SEGMENTS
- TABLE 137.GREVIS PHARMACEUTICAL PRIVATE LIMITED: PRODUCT PORTFOLIO
- TABLE 138.GREVIS PHARMACEUTICAL PRIVATE LIMITED: NET SALES,
- TABLE 139.GREVIS PHARMACEUTICAL PRIVATE LIMITED: KEY STRATERGIES
- TABLE 140.INDOCO REMEDIES LTD.: COMPANY SNAPSHOT
- TABLE 141.INDOCO REMEDIES LTD.: OPERATING SEGMENTS
- TABLE 142.INDOCO REMEDIES LTD.: PRODUCT PORTFOLIO
- TABLE 143.INDOCO REMEDIES LTD.: NET SALES,
- TABLE 144.INDOCO REMEDIES LTD.: KEY STRATERGIES
- TABLE 145.JABS BIOTECH PVT. LTD.: COMPANY SNAPSHOT
- TABLE 146.JABS BIOTECH PVT. LTD.: OPERATING SEGMENTS
- TABLE 147.JABS BIOTECH PVT. LTD.: PRODUCT PORTFOLIO
- TABLE 148.JABS BIOTECH PVT. LTD.: NET SALES,
- TABLE 149.JABS BIOTECH PVT. LTD.: KEY STRATERGIES
- TABLE 150.JAWA PHARMACEUTICALS PVT. LTD: COMPANY SNAPSHOT
- TABLE 151.JAWA PHARMACEUTICALS PVT. LTD: OPERATING SEGMENTS
- TABLE 152.JAWA PHARMACEUTICALS PVT. LTD: PRODUCT PORTFOLIO
- TABLE 153.JAWA PHARMACEUTICALS PVT. LTD: NET SALES,
- TABLE 154.JAWA PHARMACEUTICALS PVT. LTD: KEY STRATERGIES
- TABLE 155.JOHNSON & JOHNSON SERVICES INC: COMPANY SNAPSHOT
- TABLE 156.JOHNSON & JOHNSON SERVICES INC: OPERATING SEGMENTS
- TABLE 157.JOHNSON & JOHNSON SERVICES INC: PRODUCT PORTFOLIO
- TABLE 158.JOHNSON & JOHNSON SERVICES INC: NET SALES,
- TABLE 159.JOHNSON & JOHNSON SERVICES INC: KEY STRATERGIES
- TABLE 160.NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 161.NOVARTIS AG: OPERATING SEGMENTS
- TABLE 162.NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 163.NOVARTIS AG: NET SALES,
- TABLE 164.NOVARTIS AG: KEY STRATERGIES
- TABLE 165.OCULAR THERAPEUTICS, INC: COMPANY SNAPSHOT
- TABLE 166.OCULAR THERAPEUTICS, INC: OPERATING SEGMENTS
- TABLE 167.OCULAR THERAPEUTICS, INC: PRODUCT PORTFOLIO
- TABLE 168.OCULAR THERAPEUTICS, INC: NET SALES,
- TABLE 169.OCULAR THERAPEUTICS, INC: KEY STRATERGIES
- TABLE 170.SANTEN PHARMACEUTICALS CO. LTD.: COMPANY SNAPSHOT
- TABLE 171.SANTEN PHARMACEUTICALS CO. LTD.: OPERATING SEGMENTS
- TABLE 172.SANTEN PHARMACEUTICALS CO. LTD.: PRODUCT PORTFOLIO
- TABLE 173.SANTEN PHARMACEUTICALS CO. LTD.: NET SALES,
- TABLE 174.SANTEN PHARMACEUTICALS CO. LTD.: KEY STRATERGIES
- TABLE 175.SPECTRA VISION CARE PVT. LTD: COMPANY SNAPSHOT
- TABLE 176.SPECTRA VISION CARE PVT. LTD: OPERATING SEGMENTS
- TABLE 177.SPECTRA VISION CARE PVT. LTD: PRODUCT PORTFOLIO
- TABLE 178.SPECTRA VISION CARE PVT. LTD: NET SALES,
- TABLE 179.SPECTRA VISION CARE PVT. LTD: KEY STRATERGIES
- TABLE 180.SUN PHARMACEUTICALS INDUSTRIES LTD: COMPANY SNAPSHOT
- TABLE 181.SUN PHARMACEUTICALS INDUSTRIES LTD: OPERATING SEGMENTS
- TABLE 182.SUN PHARMACEUTICALS INDUSTRIES LTD: PRODUCT PORTFOLIO
- TABLE 183.SUN PHARMACEUTICALS INDUSTRIES LTD: NET SALES,
- TABLE 184.SUN PHARMACEUTICALS INDUSTRIES LTD: KEY STRATERGIES
- TABLE 185.TEVA PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT
- TABLE 186.TEVA PHARMACEUTICAL INDUSTRIES LTD: OPERATING SEGMENTS
- TABLE 187.TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
- TABLE 188.TEVA PHARMACEUTICAL INDUSTRIES LTD: NET SALES,
- TABLE 189.TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.CONJUNCTIVITIS TREATMENT MARKET SEGMENTATION
- FIGURE 2.CONJUNCTIVITIS TREATMENT MARKET,2021-2031
- FIGURE 3.CONJUNCTIVITIS TREATMENT MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.CONJUNCTIVITIS TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.CONJUNCTIVITIS TREATMENT MARKET,BY DRUG CLASS,2021(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ANTIBIOTICS CONJUNCTIVITIS TREATMENT MARKET,2021-2031(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ANTIVIRAL CONJUNCTIVITIS TREATMENT MARKET,2021-2031(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF ANTI-ALLERGIC CONJUNCTIVITIS TREATMENT MARKET,2021-2031(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF ARTIFICIAL TEARS CONJUNCTIVITIS TREATMENT MARKET,2021-2031(%)
- FIGURE 17.CONJUNCTIVITIS TREATMENT MARKET,BY DISEASE TYPE,2021(%)
- FIGURE 18.COMPARATIVE SHARE ANALYSIS OF ALLERGIC CONJUNCTIVITIS CONJUNCTIVITIS TREATMENT MARKET,2021-2031(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF BACTERIAL CONJUNCTIVITIS CONJUNCTIVITIS TREATMENT MARKET,2021-2031(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF VIRAL CONJUNCTIVITIS CONJUNCTIVITIS TREATMENT MARKET,2021-2031(%)
- FIGURE 21.CONJUNCTIVITIS TREATMENT MARKET,BY DISTRIBUTION CHANNEL,2021(%)
- FIGURE 22.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACY CONJUNCTIVITIS TREATMENT MARKET,2021-2031(%)
- FIGURE 23.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACY CONJUNCTIVITIS TREATMENT MARKET,2021-2031(%)
- FIGURE 24.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACY CONJUNCTIVITIS TREATMENT MARKET,2021-2031(%)
- FIGURE 25.CONJUNCTIVITIS TREATMENT MARKET BY REGION,2021
- FIGURE 26.U.S. CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 27.CANADA CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 28.MEXICO CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 29.GERMANY CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 30.FRANCE CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 31.UK CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 32.ITALY CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 33.SPAIN CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 34.REST OF EUROPE CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 35.JAPAN CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 36.CHINA CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 37.AUSTRALIA CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 38.INDIA CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 39.SOUTH KOREA CONJUNCTIVITIS TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 40.REST OF ASIA-PACIFIC CONJUNCTIVITIS TRE
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
